Comparing the effects of sitagliptin and empagliflozin on blood glucose , lipid profiles, blood pressure and body mass index in type2 dibetics patients treated with Metformi

Phase 3

Recruiting

• Conditions: Type 2 diabetes.; Type 2 diabetes mellitus with hyperosmolarity

• Registration Number: IRCT20191231045959N1
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 February 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Treated with metformin or metformin in combination with sulfonylureas
HbA1C between 7 and 9 percent.

Exclusion Criteria

Having any cardiovascular, inflammatory, autoimmune disease
Pregnancy and lactation
Active Liver disease
Advanced Renal failure

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Blood Suger. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;Systolic and diastolic blood pressure. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;Lipid Profile. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;Body Mass Index. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Weight.